Certolizumab Pegol
Protein / enzyme biologic targets TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | CIMZIA | — | 2009-05-13 – 2024-09-13 | fda.gov ↗ |
| Approved | EU (EMA) | Cimzia | — | 2009-10-01 | europa.eu ↗ |
| Refused (EMA) | EU (EMA) | Cimzia | — | 2008-05-21 | europa.eu ↗ |
| Approved | US (FDA) | CIMZIA | — | 2008-04-22 | fda.gov ↗ |
Trials 89 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04740814 | Feb 2021 → Jan 2022 | rheumatoid arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT04163016 | Jun 2020 → May 2023 | Crohn disease, psoriasis, psoriatic arthritis, spondyloarthropathy | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT02365948 | Mar → Aug 2015 | — | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02154425 | Sep 2014 → Dec 2015 | Crohn disease, ankylosing spondylitis, psoriatic arthritis | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02019602 | Jan 2014 → Oct 2016 | Crohn disease, ankylosing spondylitis, psoriatic arthritis | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01091220 | Mar 2010 → Mar 2011 | spermatogenic failure | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00813774 | Feb → Jul 2008 | — | UCB Pharma | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT03215277 | Oct 2017 → May 2020 | ankylosing spondylitis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03152058 | May 2017 → Dec 2027 expected | antiphospholipid syndrome, pregnancy disorder | David Ware Branch | Recruiting | No outcome recorded |
| Phase 2 | NCT02293590 | Nov 2013 → Dec 2017 | rheumatoid arthritis | Rüdiger B. Müller | Completed | No outcome recorded |
| Phase 2 | NCT01090154 | Dec 2010 → Dec 2021 | ulcerative colitis | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT01190410 | Aug 2010 → Nov 2017 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00329550 | May 2006 → Apr 2008 | Crohn disease | UCB Japan Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00329420 | May 2006 → May 2008 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00329303 | Apr 2006 → May 2007 | psoriasis | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00291668 | Mar 2006 → Nov 2007 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00245765 | Oct 2005 → Nov 2006 | psoriasis | UCB Pharma | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03051217 | Feb 2017 → Nov 2018 | psoriasis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 2/3 | NCT00791999 | Nov 2008 → Jan 2010 | rheumatoid arthritis | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 352 trials | ||||||
| Phase 3 | NCT04643483 | Jun 2021 → Sep 2023 | Crohn disease | UCB Biopharma SRL | Withdrawn | No outcome recorded |
| Phase 3 | NCT04610476 | Oct 2020 → Oct 2024 | psoriatic arthritis, substance withdrawal syndrome | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT04123795 | Jan 2020 → Apr 2026 overdue | psoriasis | UCB Biopharma SRL | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03357471 | Nov 2017 → Jul 2018 | ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT02552212 | Sep 2015 → May 2018 | spondyloarthropathy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02505542 | Jul 2015 → Feb 2019 | ankylosing spondylitis | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02346240 | Feb 2015 → Mar 2016 | psoriasis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT02326298 | Dec 2014 → Mar 2016 | psoriasis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT02326272 | Dec 2014 → Jan 2016 | psoriasis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT02319642 | Nov 2014 → Dec 2016 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT02151851 | Jul 2014 → Jun 2016 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01590966 | Oct 2012 → Mar 2019 | rheumatoid arthritis, spondyloarthropathy | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 3 | NCT01550003 | Mar 2012 → Apr 2024 | polyarticular juvenile idiopathic arthritis | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01521923 | Jan 2012 → Jul 2015 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01519791 | Jan 2012 → Jul 2014 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01374971 | Sep 2011 → Jul 2012 | rheumatoid arthritis | Nathan Wei, MD, FACP, FACR | Completed | No outcome recorded |
| Phase 3 | NCT01292265 | Feb 2011 → Jan 2012 | rheumatoid arthritis | UCB Pharma | Terminated | No outcome recorded |
| Phase 3 | NCT02586246 | Jan 2011 → May 2013 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01235598 | Dec 2010 → Sep 2012 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01213017 | Sep 2010 → Jan 2011 | rheumatoid arthritis | Oklahoma Medical Research Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01087762 | Mar 2010 → Oct 2011 | spondyloarthropathy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01197066 | Mar 2010 → Nov 2016 | rheumatoid arthritis | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01087788 | Mar 2010 → Nov 2011 | psoriatic arthritis | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00993317 | Oct 2009 → Aug 2011 | rheumatoid arthritis | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00850343 | Mar 2009 → May 2013 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00851318 | Mar 2009 → Jun 2013 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00843778 | Jan 2009 → Dec 2012 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00791921 | Nov 2008 → Jan 2010 | rheumatoid arthritis | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00753454 | Sep 2008 → May 2011 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00717236 | Jul 2008 → Mar 2010 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00674362 | Jun 2008 → May 2010 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00552344 | May 2008 → Dec 2014 | Crohn disease | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00552058 | Mar 2008 → Oct 2009 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00358683 | Nov 2007 → ? | Crohn disease | UCB Pharma | Withdrawn | No outcome recorded |
| Phase 3 | NCT00307931 | Apr 2007 → Aug 2008 | Crohn disease | UCB Pharma | Terminated | No outcome recorded |
| Phase 3 | NCT00354367 | Jan 2007 → ? | Crohn disease | UCB Pharma | Withdrawn | No outcome recorded |
| Phase 3 | NCT00356408 | Jan 2007 → Feb 2010 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00349752 | Nov 2006 → Jul 2009 | Crohn disease | UCB Pharma | Terminated | No outcome recorded |
| Phase 3 | NCT00333788 | Oct 2006 → Apr 2010 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00308581 | Apr 2006 → Apr 2008 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00297648 | Feb 2006 → Jan 2008 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00160641 | Nov 2005 → Feb 2012 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00175877 | Jun 2005 → Feb 2012 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00160602 | Jun 2005 → Sep 2006 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00152386 | Feb 2005 → Oct 2006 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00160524 | Jul 2004 → Aug 2012 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00160706 | Feb 2004 → May 2012 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00152425 | Feb 2004 → May 2005 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00152490 | Dec 2003 → May 2005 | Crohn disease | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00548834 | Jun 2003 → Jul 2004 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00160693 | Mar 2003 → Feb 2011 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00544154 | Oct 2002 → Jan 2004 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05115903 | Dec 2021 → Jul 2024 | spondyloarthropathy | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT03020992 | Dec 2016 → Dec 2019 | anterior uveitis, spondyloarthropathy | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 4 | NCT02597829 | Nov 2015 → May 2018 | Crohn disease | Shafran Gastroenterology Center | Unknown | No outcome recorded |
| Phase 4 | NCT02451748 | Aug 2015 → Sep 2017 | rheumatoid arthritis | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT01696942 | Feb 2013 → Jun 2016 | Crohn disease | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01443364 | Dec 2011 → May 2015 | rheumatoid arthritis | UCB Italy s.p.a. | Completed | No outcome recorded |
| Phase 4 | NCT01548768 | Oct 2011 → Sep 2019 | rheumatoid arthritis | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT01295151 | Aug 2011 → Nov 2015 | rheumatoid arthritis | Julia Brown | Completed | No outcome recorded |
| Phase 4 | NCT01255761 | Nov 2010 → Oct 2012 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT00993668 | Sep 2009 → Jun 2010 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT00580840 | Dec 2007 → Dec 2010 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07491913 | Jun 2025 → Dec 2027 expected | Takayasu arteritis | Marmara University | Recruiting | No outcome recorded |
| — | NCT04569890 | Dec 2020 → Dec 2022 | pregnancy disorder, rheumatoid arthritis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT04378621 | Oct 2020 → Sep 2025 | depressive disorder, rheumatoid arthritis, subjective cognitive decline | Vastra Gotaland Region | Unknown | No outcome recorded |
| — | NCT01053559 | Jan 2010 → Sep 2013 | Crohn disease | Shafran Gastroenterology Center | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT03559686 | — | rheumatoid arthritis | UCB Biopharma SRL | No longer available | No outcome recorded |
| — | NCT03559660 | — | Crohn disease | UCB Biopharma SRL | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02430909 Background | Apr 2015 → Apr 2017 | rheumatoid arthritis | UCB Celltech | Completed | No outcome recorded |
| Phase 2 | NCT00899678 Comparator | Apr 2009 → Jul 2012 | Crohn disease | UCB Celltech | Terminated | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02497976 Comparator | Dec 2015 → Apr 2017 | interstitial cystitis | ICStudy, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01864265 Comparator | Jul 2013 → Jun 2019 | rheumatoid arthritis | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT01817972 Comparator | Mar 2013 → Jun 2014 | Crohn disease | Gastroenterology Research of America | Unknown | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT03100253 Comparator | Mar 2018 → Dec 2021 | rheumatoid arthritis | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 4 | NCT02353780 Comparator | Mar 2015 → Dec 2017 | rheumatoid arthritis | Dr. Larry W. Moreland | Terminated | No outcome recorded |
| Phase 4 | NCT02466581 Comparator | Feb 2015 → Jul 2023 | rheumatoid arthritis | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT02236481 Comparator | Jul 2013 → Dec 2017 | rheumatoid arthritis, type 2 diabetes mellitus | Prof. Roberto Giacomelli | Terminated | No outcome recorded |
| Phase 4 | NCT01491815 Comparator | Dec 2012 → Jul 2023 | rheumatoid arthritis | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT01500278 Comparator | Dec 2011 → Nov 2015 | rheumatoid arthritis | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT01147341 Comparator | Jul 2010 → Jan 2012 | rheumatoid arthritis | Michael Schiff, MD | Completed | No outcome recorded |
| Phase 4 | NCT01024647 Comparator | Dec 2009 → May 2013 | Crohn disease | Atlanta Gastroenterology Associates | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-11-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results of two trials show a rapid and sustained response with certolizumab pegol for treatment of rheumatoid arthritis (J-RAPID and HIKARI Studies) released at 2011 meeting of American College of Rheumatology (ACR) otsuka.co.jp ↗ |
| 2008-06-10 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and UCB agreed to co-develop and co-promote Keppra and Cimzia in Japan®® otsuka.co.jp ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 113 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | certolizumab pegol | “This 24-week, placebo-controlled, double-blind, randomized study (NCT00791921) investigated efficacy and safety of certolizumab pegol (CZP) in Japanese rheumatoid arthritis...” PMID 24981319 ↗ Nov 201392“To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing...” NCT05115903 ↗ “TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi)” NCT04378621 ↗ “The anti-TNFα used in this trial is certolizumab pegol (Cimzia®), a pegylated Fab'-fragment of a monoclonal antibody with high specificity for TNFα.” NCT01590966 ↗ “Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab)” PMID 31513665 ↗ Sep 2019 “Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis” NCT00993317 ↗ “200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).” NCT01087788 ↗ “200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).” NCT01087762 ↗ “induction of Certolizumab Pegol administered subcutaneously every 2 weeks” NCT00899678 ↗ “Cimzia: Certolizumab-pegol plus Methotrexate and steroids” NCT01491815 ↗ “Certolizumab-pegol: 200 mg s.c. every other week.” NCT01491815 ↗ “* Active Substance: Certolizumab Pegol” NCT03357471 ↗ “Certolizumab pegol (Cimzia)” NCT07149792 ↗ “Certolizumab pegol” NCT02451748 ↗ |
| Known as | CDP870 | “The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms...” NCT00993317 ↗10“Multicentre, Double-blind Study to Describe the Efficacy and Safety of Re-treatment With CDP870 (Certolizumab Pegol) Subcutaneous” NCT00329303 ↗ “Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.” NCT02451748 ↗ “Certolizumab Pegol (CDP870)” NCT00152490 ↗ “Certolizumab Pegol (CDP870)” NCT00152425 ↗ “Certolizumab pegol (CDP870)” NCT00152386 ↗ |
| Known as | Certolizumab | “The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms...” NCT00993317 ↗ |
| Known as | Cimzia | “The anti-TNFα used in this trial is certolizumab pegol (Cimzia®), a pegylated Fab'-fragment of a monoclonal antibody with high specificity for TNFα.” NCT01590966 ↗14“Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.” NCT02451748 ↗ “A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)” NCT04163016 ↗ “The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.” NCT01548768 ↗ “Cimzia: Certolizumab-pegol plus Methotrexate and steroids” NCT01491815 ↗ “Certolizumab Pegol 200 MG/ML [Cimzia]” NCT04569890 ↗ “Certolizumab Pegol (CIMZIA®, CZP)” NCT03559660 ↗ “Certolizumab Pegol (Cimzia®)” NCT00329303 ↗ “Certolizumab pegol (Cimzia)” NCT07149792 ↗ |
| Known as | Cimzia (R) | “Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.” NCT02293590 ↗ |
| Known as | CZP | “This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying...” PMID 24431394 ↗ Jan 201421“The objective of this Named Patient Program (NPP) is to provide continued availability of Certolizumab Pegol (CZP) to adult Rheumatoid Arthritis (RA) patients who participated...” NCT03559686 ↗ “The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms...” NCT00993317 ↗ “This 24-week, placebo-controlled, double-blind, randomized study (NCT00791921) investigated efficacy and safety of certolizumab pegol (CZP) in Japanese rheumatoid arthritis...” PMID 24981319 ↗ Nov 2013 “The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study...” NCT04163016 ↗ “Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study.” NCT02154425 ↗ “This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.” NCT00717236 ↗ “The objective of this study was to examine the safety and benefits of certolizumab pegol (CZP)+methotrexate (MTX) treatment for almost 5 years in patients with RA.” PMID 26353833 ↗ Sep 2015 “This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants.” PMID 29030361 ↗ Oct 2017 “400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 0, 2, and 4, followed by 1 sc injection at weeks 6, 8, and 10.” NCT01147341 ↗ “Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.” NCT00175877 ↗ “Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.” NCT02293590 ↗ “Certolizumab pegol (CZP) is an effective therapy for Crohn's disease refractory to aminosalicylates, corticosteroids and immunosuppressants.” PMID 20491747 ↗ May 2010 “Certolizumab pegol (CZP), a PEGylated, Fc-free anti-TNF agent approved for the treatment of rheumatic diseases and/or Crohn's disease” PMID 29623679 ↗ Jul 2018 “Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.” NCT00160641 ↗ “CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate.” NCT01374971 ↗ “200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).” NCT01087788 ↗ “in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA)” PMID 31177099 ↗ Jun 2019 “Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent.” PMID 22413944 ↗ Jun 2012 “Certolizumab Pegol (CIMZIA®, CZP)” NCT03559660 ↗ “Certolizumab Pegol (CZP)” NCT01550003 ↗ “Certolizumab Pegol (CZP)” NCT01255761 ↗ |
| Known as | UCB product: Certolizumab Pegol (CDP870) | “UCB product: Certolizumab Pegol (CDP870)” NCT01374971 ↗ |
| Action | Inhibit | “a novel PEGylated anti-tumor necrosis factor agent” PMID 18975346 ↗ Nov 2008 |
| Modality | Protein / enzyme biologic | “pegylated humanized Fab' fragment” PMID 17634459 ↗ Jul 2007 |
| Route | Subcutaneous | “treatment with subcutaneous certolizumab pegol at an initial dosage of 400 mg given at weeks 0, 2, and 4, with a subsequent dosage of 200 mg or 400 mg given every 2 weeks” PMID 18975346 ↗ Nov 2008 |
| Target | TNF | “Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor alpha.” PMID 17634458 ↗ Jul 2007 |